Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

By afschroeder • April 23, 2026

Fakih M, Gill S, Sampat K, Chan DL, Fisher G, Cruz-Correa M, Lenz HJ, Garcia-Alfonso P, Forget F, Lonardi S, Krauss J, Chen E, Cubillo Gracian A, Liu Y, van Buuren N, Shao J, Dong M, Chen A, Tejani M, Hecht JR. Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer. ESMO Gastrointest Oncol. 2026 Apr 17;12:100324. doi: 10.1016/j.esmogo.2026.100324. PMID: 42022129; PMCID: PMC13098452.

Tags: Bevacizumab, FOLFIRI, Hematology/Oncology, magrolimab, Metastatic colorectal cancer, Publications

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial

Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney MS, Woszczyk D, Giannopoulos K, Jurczak W, Jing J, Li[...]

Personalizing cancer care for older adults

Ji J, Sedrak MS. Personalizing cancer care for older adults. J Gerontol A Biol Sci Med Sci. 2026 Jun 6;81(7):glag126. doi: 10.1093/gerona/glag126. PMID: 42329168; PMCID:[...]

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer

Zheng S, Sullivan P, Vadehra K, Kim J, Levee A, Callahan R, Teshome M, Tseng CH, Bardia A, Kapoor NS. Receptor discordance between primary tumors[...]